Genzyme in Belgium

Our sales, marketing and corporate affairs offices in Zaventem

Genzyme established its first offices in Belgium in 1993 to support European expansion of its diagnostics and therapeutics sales activities. In 2000, with the acquisition of BioMatrix, Genzyme Belgium expanded to include a team of sales and marketing professionals for Belgium and Luxembourg. Since 2002, Genzyme Belgium operates from Zaventem, just outside the Brussels region, and comprises all business activities for the Belux region as well as some international and European functions. It also houses Genzyme’s Corporate Affairs department for Europe.

Our manufacturing facilities in Geel

In October 2001, Genzyme Corporation acquired the Belgian part of Pharming N.V. in Geel, Belgium to develop Genzyme’s first biotherapeutics manufacturing facility in Europe.

The manufacturing facility comprises a continuous production line for the manufacturing of enzymes for enzyme replacement therapies and a fed-batch production line for the manufacturing of therapeutic monoclonal antibodies.

The first product is the enzyme replacement therapy for Pompe disease, a rare genetic, often fatal, disease of the muscle. Regulatory approval for commercial production of this enzyme was received in 2009-2010 for the EU, Japan, Canada, US and Brazil.

The monoclonal antibody produced in Geel can be used for the treatment of B-CLL leukemia. The approval for its manufacturing for the EU and the US was received in 2009 and 2010.

Genzyme’s overall investment in Geel totals around 350 million and the site currently employs 450 people.

Terms and Conditions of Use | Privacy Policy | © 2012 Genzyme Corporation, a Sanofi company. All rights reserved.